The Oncotest™ Enables Physicians
Improve Therapy Selection To Deliver the Right Drug to the Right Patient
at the Right Time
Cancer of Unknown Origin
Oncologists have limited to no guidelines which therapy to choose. We help them to avoid selecting ineffective drugs
Overcoming Recurring Ovarian Cancer
Gyn-onc surgeons can provide patient specimen during surgery. Enabling you to avoid tumor resistance to your therapy
Avoiding Glioblastoma Resistance
Neurosurgeons can send surgically removed tissue samples. To leverage our tumor resistance assay, the SAGE Oncotest™.
For Late-Stage Patients
When the course of treatment has failed
Leverage the full NCCN guidelines to get best possible outcome.To find the needle in the haystack.
“Advance beyond standard of care within standard of care.”
How the Oncotest™ Works:
1
We create live 3D microtumors of the patient’s biopsy in a day
2
that retain the microenvironment and heterogeneity of the biopsy
3
that retain the microenvironment and heterogeneity of the biopsy
4
to identify the most effective therapy in just one week.
Non-Response to extremely high in vitro dosages predicts tumor resistance with
high accuracy
Experiment
- Fresh patient sample shipped overnight
- Cultured with extremely high drug doses over 5 days
- Labelled with T3-Thymidine
- Treatment effects are classified into 3 groups
- Resistant (red): 0-40%
- Intermediate (gray): 40-80%
- Potentially Sensitive (green): >80%
Results
- If the effect of an extremely high drug dosage was less than 40%, non of the patients responded to the therapy.
- However, if the effect of an extremely high drug dosage was more than 80%, patients were most likely to respond, although it did not guarantee it.
Conclusion
- An extreme drug resistance assay can reliably predict tumor resistance but prediction on tumor sensitivity is less reliable.
